Cerebral Infarction, Myocardial Infarction
Conditions
Keywords
adiponectin, cardiovascular diseases, cerebrovascular diseases
Brief summary
Adiponectin (Ad) is an abundant protein in human body, and reports have shown that it act as a novel risk factor for brain and heart ischemia injury. This 5 years follow-up study will focus on serum adiponectin concentration, activity and isoforms in Chinese population and its correlation to these diseases.
Detailed description
Adiponectin (Ad) is an abundant protein hormone regulatory of numerous metabolic processes, anti-inflammatory, vascular protective, and anti-ischemic properties. Since its 1995 discovery, Ad has garnered considerable attention for its role in diabetic and cardiovascular pathology. Clinical observations have demonstrated the association of hypoadiponectinemia in patients with obesity, cardiovascular disease, and insulin resistance. There is growing evidence supporting Ad can act as a novel risk factor for cardiovascular and cerebrovascular injury. This 5 years follow-up study will focus on serum adiponectin concentration, activity and isoforms in Chinese population and its correlation to cardiovascular and cerebrovascular diseases.
Interventions
None listed
Sponsors
Xijing Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
Yes
Inclusion criteria
* available for 5 years of follow-up study
Exclusion criteria
* Death caused other than cardiovascular and cerebralvascular diseases till the study ends * Floating Population * Pregnancy, lactation, or child bearing women * Tumor * Active hepatic disease or hepatic dysfunction, or AST/ALT \> 1.5UNL * Severe renal dysfunction(Scr \> 3 mg/dl or 264μmol/L) * Patients with any condition which, in the investigator's judgment, might increase the risk to the subject for any adverse event or abnormal laboratory finding
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants with major adverse events | 5 years | Major adverse events included but were not limited to death during the study caused by cardiovascular events or cerebrovascular events. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| blood routine, glucose and lipid profile; ECG; | 5 years | the tests mentioned above will be taken once per year |
| serum adiponectin concentration, activity and isoforms | 5 years | serum adiponectin concentration, activity and isoforms will be monitored once per year. |
Countries
China
Contacts
Primary ContactLing Tao, M.D Ph.D
Outcome results
None listed